Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes

References

• Corpas FJ, Barroso JB, Sandalio LM, et al. Peroxisomal NADP-Dependent isocitrate dehydrogenase. Characterization and activity regulation during natural senescence. Plant Physiol. 1999;121(3):921–928.
   PubMed Web of Science ®Google Scholar
• Ploumakis A, Coleman ML. OH, the places you’ll go! Hydroxylation, gene expression, and cancer. Mol Cell. 2015;58(5):729–741.
   PubMed Web of Science ®Google Scholar
• Dong C, Zhang H, Xu C, et al. Structure and function of dioxygenases in histone demethylation and DNA/RNA demethylation. IUCrJ. 2014;1(Pt 6):540–549.
   PubMedGoogle Scholar
• Garrett-Bakelman FE, Melnick AM. Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics. 2016;8(7):945–957.
   PubMed Web of Science ®Google Scholar
• Yang H, Ye D, Guan KL, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–5571.
   PubMed Web of Science ®Google Scholar
• Huang J, Yu J, Tu L, et al. Isocitrate dehydrogenase mutations in Glioma: from basic discovery to therapeutics development. Front Oncol. 2019;9:506.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465(7300):966.
   PubMed Web of Science ®Google Scholar
• Losman JA, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836–852.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Wilson ER, Helton NM, Heath SE, et al. Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia. 2022;36(4):935–945.
   PubMed Web of Science ®Google Scholar
• Cazzola M. IDH1 and IDH2 mutations in myeloid neoplasms–novel paradigms and clinical implications. Haematologica. 2010;95(10):1623–1627.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488(7413):656–659.
   PubMed Web of Science ®Google Scholar
• Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014;14(3):329–341.
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273–277.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–281.
   PubMed Web of Science ®Google Scholar
• Ruminy P, Marchand V, Buchbinder N, et al. Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. Leukemia. 2016;30(3):757–760.
   PubMed Web of Science ®Google Scholar
• Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–3584.
   PubMed Web of Science ®Google Scholar
• Arbab Jafari P, Ayatollahi H, Sadeghi R, et al. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. Hematology. 2018;23(10):778–784.
   PubMed Web of Science ®Google Scholar
• Mason EF, Kuo FC, Hasserjian RP, et al. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. Am J Hematol. 2018;93(4):504–510.
   PubMed Web of Science ®Google Scholar
• Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119(2):559–568.
   PubMed Web of Science ®Google Scholar
• Lin CC, Hou HA, Chou WC, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. 2014;89(2):137–144.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang X, Wang XQD, et al. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood. 2020;135(11):845–856.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575–2584.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478–493.
   PubMed Web of Science ®Google Scholar
• Ogawara Y, Katsumoto T, Aikawa Y, et al. Kitabayashi I: IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and Hypoxia pathways in acute myeloid leukemia. Cancer Res. 2015;75(10):2005–2016.
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Guan Y, et al. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2022;6(1):100–107.
   PubMed Web of Science ®Google Scholar
• Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol. 2013;98(6):648–657.
   PubMed Web of Science ®Google Scholar
• Mason EF, Hasserjian RP, Aggarwal N, et al. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv. 2019;3(21):3322–3332.
   PubMed Web of Science ®Google Scholar
• Boutzen H, Saland E, Larrue C, et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016;213(4):483–497.
   PubMed Web of Science ®Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Investigators A-C-S: differentiation syndrome associated with Enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res. 2020;26(16):4280–4288.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291.
   PubMed Web of Science ®Google Scholar
• Kovy P, Orfi Z, Bors A, et al. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS One. 2021;16(6):e0253386.
   PubMed Web of Science ®Google Scholar
• Ferret Y, Boissel N, Helevaut N, et al. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica. 2018;103(5):822–829.
   PubMed Web of Science ®Google Scholar
• Wiseman DH, Williams EL, Wilks DP, et al. Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. Leukemia. 2016;30(9):1946–1950.
   PubMed Web of Science ®Google Scholar
• Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6(39):42345–42353.
   PubMedGoogle Scholar
• Ok CY, Loghavi S, Sui D, et al. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019;104:305–311.
   PubMed Web of Science ®Google Scholar
• Middeke JM, Metzeler KH, Rollig C, et al. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2021;6(5):1394–1405.
   Web of Science ®Google Scholar
• Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827–2837.
   PubMed Web of Science ®Google Scholar
• Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015;90(5):E77–E79.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of Venetoclax and Azacitidine in treatment-naive patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753–2761.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–1531.
   PubMed Web of Science ®Google Scholar